The market for Digital Pathology is expected to reach US$ XX Bn to 2020.
Digital pathology refers to the use of digital tools and solutions for the automation of pathology processes and lab testing. The growing prevalence of cancer and chronic diseases, increasing demand for rapid pathological tests, and automation of the healthcare system are some of the major factors that facilitated the advent of digital pathology. Digital pathology conveniently improves workflow efficiency and delivers faster and more accurate test results than conventional methods. Other factors driving the growth of the digital pathology market are ease of reach to remote areas, efficient record-keeping, and reduction in diagnosis cost.
Technologies such as slide imaging find the widest application in pharmaceutical research. High-resolution sample scanning, cloud storage of diagnostics data, ease of interpretation of voluminous data, and data sharing are some of the prime features that have led to the rapid adoption of digital pathology in the pharmaceutical sector. Though the concept of digital pathology has been known for over a decade, it has only recently received its fair share of fame attributed to the latest technological advancements and its capability in cost containment in long-term applications. The high prevalence of cancer and the resultant urgency in rapid screening and diagnosis to deliver better treatment outcomes is also a significant factor that has urged the growth in demand for digital pathology in the field of disease diagnosis.
Leica Biosystems, Philips Healthcare, Ventana Medical Systems, Inc., Visiopharm A/S, Omnyx, LLC, Hamamatsu Photonics Inc., Definiens, 3DHISTECH Ltd., Nikon Instruments and several others
The market for Digital Pathology is expected to reach US$ XX Bn to 2020.
The Digital Pathology market is expected to see significant CAGR growth over the coming years, at XX%.
The report is forecasted to 2020.
The base year of this report is 2021.